Advertisement

Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer

Published:February 02, 2019DOI:https://doi.org/10.1016/j.jgo.2019.01.016
      With technological advancements in the field of precision medicine through broad-based genomic sequencing (BGS), the interrogation of an individual's tumor genome sequence is now possible in the course of routine clinical care. BGS allows for assessments of clinical trial eligibility and potential matching with emerging targeted treatments [
      • Li T.
      • et al.
      Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies.
      ,
      • NCCN
      Non-Small Cell Lung Cancer v 5.2017.
      ]. For this reason, the National Comprehensive Cancer Network (NCCN) guidelines strongly advises BGS in patients with advanced non-small cell lung cancer (aNSCLC) [
      • NCCN
      Non-Small Cell Lung Cancer v 5.2017.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Li T.
        • et al.
        Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies.
        J Clin Oncol. 2013; 31: 1039-1049
        • NCCN
        Non-Small Cell Lung Cancer v 5.2017.
        (Available from)
        • Wong M.L.
        • et al.
        Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: a nationally representative cohort study.
        Lung Cancer. 2016; 102: 108-117
        • Shavers V.L.
        • Brown M.L.
        Racial and ethnic disparities in the receipt of cancer treatment.
        J Natl Cancer Inst. 2002; 94: 334-357
        • Davis B.A.
        • et al.
        Racial and ethnic disparities in oncotype dx test receipt in a statewide population-based study.
        J Natl Compr Canc Netw. 2017; 15: 346-354
        • Bach P.B.
        • et al.
        Racial differences in the treatment of early-stage lung cancer.
        N Engl J Med. 1999; 341: 1198-1205
        • Hardy D.
        • et al.
        Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer.
        Cancer. 2009; 115: 2199-2211
      1. Flatiron Health Database.
        July 2016 (Accessed)
        • Zip Code Census File for SEER-Medicare Patients
        SEER-Medicare: Geographic Area Data.
        2014
        • Awad M.M.
        • et al.
        MET Exon 14 Mutations in Non–Small-Cell Lung Cancer are Associated with Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
        J Clin Oncol. 2016; 34: 721-730
        • Murthy V.H.
        • Krumholz H.M.
        • Gross C.P.
        Participation in cancer clinical trials: Race-, sex-, and age-based disparities.
        JAMA. 2004; 291: 2720-2726
        • Kuo C.W.
        • et al.
        Non-small cell lung cancer in very young and very old patients.
        Chest. 2000; 117: 354-357
        • Subramanian J.
        • et al.
        Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis.
        J Thorac Oncol. 2010; 5: 23-28
        • Arbes Jr., S.J.
        • et al.
        Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States).
        Cancer Causes Control. 1999; 10: 513-523
        • Xu Y.
        • et al.
        Disparities in Geographic Accessibility of National Cancer Institute Cancer Centers in the United States.
        J Med Syst. 2017; 41: 203